Bristol-Myers Squibb has partnered with PureTech Health subsidiary Vedanta Biosciences to study its Opdivo in combination with VE800 drug candidate for the treatment of advanced or metastatic cancers.

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, while Vedanta Biosciences’ VE800 is a microbiome-derived immuno-oncology product.

As per the terms of the agreement, Vedanta Biosciences will retain control of the VE800 programme, including global research and development (R&D) and commercial rights.

Bristol-Myers Squibb oncology, development head Fouad Namouni said: “Vedanta Biosciences is a leading company focused on the characterization of immunomodulatory human gut commensals and the development of live bacterial products for the potential treatment of human diseases.

“Our collaboration with Vedanta Biosciences will allow us to gain a deeper understanding about the emerging microbiome landscape, its role in oncology, and the potential to improve outcomes for patients with advanced or metastatic cancer.”

In various cancer preclinical models, VE800 demonstrated ability to trigger CD8+ T cells, stimulate the attack of immune system on tumour cells and significantly enhance the anti-PD-1 therapy effects.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Through this collaboration our goal is to determine whether VE800 in combination with Opdivo can improve outcomes for patients with advanced or metastatic cancers.”

The partners noted that these findings support clinical research to evaluate the potential of modulating the microbiome with VE800 to strengthen the efficacy of checkpoint inhibitors.

Vedanta Biosciences co-founder and CEO Bernat Olle said: “Our lead, microbiome-based immuno-oncology candidate, VE800, is based on work conducted in collaboration with our co-founder, Dr Kenya Honda, showing in preclinical models that certain gut-dwelling bacterial strains potentiate cytotoxic CD8+ T cells and enhance infiltration into tumours.

“Through this collaboration our goal is to determine whether VE800 in combination with Opdivo can improve outcomes for patients with advanced or metastatic cancers.”

In conjunction with the immuno-oncology alliance, Bristol-Myers is planning to make an equity investment in Vedanta Biosciences.

The investment is subject to the completion of due diligence, negotiation by the parties of definitive transaction agreements and receipt of all requisite approvals by Bristol-Myers.